Core Viewpoint - Oddity Tech Ltd. and certain executives are facing charges for failing to disclose material information during the Class Period, which is a violation of federal securities laws [1]. Group 1: Legal Proceedings - Investors have until September 17, 2024, to file lead plaintiff applications in a securities class action lawsuit against Oddity, covering purchases made between July 19, 2023, and May 20, 2024 [2]. - The lawsuit is currently pending in the United States District Court for the Eastern District of New York [2]. - The case is identified as Hoare v. Oddity Tech Ltd., et al., 24-cv-05037 [5]. Group 2: Allegations Against Oddity - NINGI Research reported multiple allegations against Oddity, claiming the company misled investors about critical aspects of its business [4]. - Allegations include that Oddity's AI is merely a questionnaire and that its reported "repeat purchase rates" are due to customers unknowingly entering non-cancelable plans [4]. - NINGI also found numerous undisclosed lawsuits against Oddity and its subsidiaries in the US and Israel, often related to unpaid bills and consumer protection law violations [4]. Group 3: Market Reaction - Following the news of the allegations, Oddity's share price dropped by $3.02, or 7.37%, closing at $37.97 per share on May 21, 2024 [7].

NEW ORLEANS, July 23, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. ("Oddity" or the "Company") (NasdaqGM: ODD), if they purchased the Company's securities between July 19, 2023 and May 20, 2024, inclusive (the "Class Period"). This action is pending in the United State ...

Click here to participate in the action. If you purchased or otherwise acquired Oddity Tech shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you ...

These are just a few of the metrics contributing to GMAB's Value grade of B and TECH's Value grade of D. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits. Value investors also tend to look at a n ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels. Another notable valuation metric for GMAB is its P/B ratio of 3.57. The P/B ...

CETI's focus is to treat and repurpose a substantial amount of the water it receives from oil fields. Posttreatment, this water can be reused by oil companies, in agriculture, or even as drinking water where needed. Globally, agriculture consumes about 70% of freshwater resources, making CETI's water remediation capabilities particularly valuable to local communities and Industries. ABOUT CYBER ENVIRO-TECH, INC. CETI is an international eco-conscious, oil/sludge, water and soil remediation Company. Using bi ...

CETI's proprietary products and systems utilize environmentally friendly biologics which negate the need for chemical inputs and create a simpler process which reduces operational costs and initial capital outlay. In addition, CETI's water remediation approach has a much higher Standard Removal Proficiency by achieving 100% removal efficiency, far exceeding alternative approaches like ADS/DEP. These traditional processes only reach an approximate 43% removal, or 66% with more chemicals. "I find myself inund ...

MINNEAPOLIS, May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of spe ...

ST. PAUL, Minn., May 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene therapies (CGT). The G-Rex® Grant Program will provide academic and commercial institutions engaged in IND enabling preclinical research, process development, and/or ongoing GMP manufacturing of cell and gene therapies with the ...

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal ...